Anti-HER2 (Trastuzumab biosimilar - IgG1 isotype)
Product | Unit size | Cat. code | Docs. | Qty. | Price | |
---|---|---|---|---|---|---|
Anti-HER2-Tra-hIgG1 HER2 (trastuzumab) antibody - Human IgG1 |
Show product |
100 µg 1 mg (10 x 100 µg) |
her2tra-mab1
|
|
Monoclonal human IgG1 antibody against HER2
Anti-HER2-Tra-hIgG1 is the biosimilar of the clinical antibody trastuzumab. Anti-HER2-Tra-hIgG1 features the constant region of the human IgG1 isotype and the variable region of trastuzumab. Trastuzumab is a humanized IgG1 monoclonal antibody that targets the HER2 receptor (also known as HER2/neu) that is found on the cell membrane of epithelial cells.
HER2 plays an important role in normal cell growth and differentiation [1]. However, in certain types of cancers, particularly in breast and ovarian cancers, HER2 is over-expressed and causes uncontrollable cell proliferation. Binding of trastuzumab to HER2 results in cell death through different mechanisms including antibody-dependent cell-mediated cytotoxicity and phagocytosis [2, 3]. Trastuzumab has been approved by the FDA for the treatment of breast cancer.
Anti-HER2-Tra-hIgG1 was generated by recombinant DNA technology. It has been produced in Chinese hamster ovary (CHO) cells and purified by affinity chromatography with protein G.
References:
1. Rubin I. & Yarden Y. 2001. The basic biology of HER2. Ann Oncol.12 Suppl 1:S3-8.
2. Collins DM. et al., 2012. Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines. Ann Oncol. 23(7):1788-95.
3. Petricevic B. et al., 2013. Trastuzumab mediates antibody-dependent cell- mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients. J Transl Med. 11:307.
Specifications
Specificity: Targets cells expressing HER2
Clonality: Monoclonal antibody
Clone: Trastuzumab (Anti-HER2-hIgG1, kappa)
Isotype: Human IgG1, kappa
Control: Human IgG1
Source: CHO cells
Formulation: 0.2 µm filtered solution in 68 mM sodium phosphate buffer (pH 7.4) with 91 mM glycine, 5% w/v saccharose, and stabilizing agents
Purity: Purified by affinity chromatography with protein G
Tested application: Flow cytometry
Quality control:
- Binding of Anti-HER2-Tra-hIgG1 to HER2 has been tested using flow cytometry.
- The complete sequence of this antibody has been verified.
- The absence of bacterial contamination (e.g. lipoproteins and endotoxins) has been confirmed using HEK-Blue™ TLR2 and HEK-Blue™ TLR4 cells.
Contents
Anti-HER2-Tra-hIgG1 purified monoclonal antibody (mAb) is provided azide-free and lyophilized. It is available in two quantities:
- her2tra-mab1: 100 µg
- her2tra-mab1-1: 10 x 100 µg (1 mg)
Product is shipped at room temperature
Upon receipt, store at -20°C.
Tags: buy Trastuzumab (anti-HER2) | Trastuzumab (anti-HER2) supplier | purchase Trastuzumab (anti-HER2) | Trastuzumab (anti-HER2) cost | Trastuzumab (anti-HER2) manufacturer | order Trastuzumab (anti-HER2) | Trastuzumab (anti-HER2) distributor
Back to the top